Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that additional gastrointestinal (GI) surgeons in the US have performed successful treatments in both upper and lower GI cases using Creo’s Speedboat device powered by the Company’s CROMA Advanced Energy platform.

Following the first successful treatment of patients in the US with Speedboat, announced in January 2019, Speedboat has now been used successfully by a further four GI surgeons. Furthermore, at a recent scientific conference, Speedboat was demonstrated during a live case to an audience of leading therapeutic GI endoscopists. During the same conference, many of these leading therapeutic endoscopists were able to get a hands-on introductory experience with Speedboat in a training environment with excellent feedback, in particular with regards to the safety profile Speedboat provides the endoscopist.

This brings the total number of doctors now trained in the US to six at five hospitals across the East and West coasts. Creo will be working very closely with these centres as further cases are carried out, along with providing a continuing Clinical Education programme.

All of these initial users of Speedboat form part of the Creo’s education led strategy to identify and develop the training centres of the future, not only in the US market but also throughout our distribution network. This considered and targeted approach represents our investment in the future of the business. Speedboat is the first device of a range of GI devices to be cleared for use with the CROMA Advanced Energy platform that uniquely harnesses the use of bipolar radiofrequency energy for precise tissue dissection along with microwave energy for highly controlled coagulation and tissue ablation.

Dr Zacharias Tsiamoulos, Consultant in Gastroenterology and Specialist in GI Endoscopy at the East Kent University Hospitals Foundation Trust, has been overseeing training to the US surgeons on the techniques required to successfully undertake procedures utilising Speedboat. Speedboat helps to reduce the risks associated with alternative open, laparoscopic and existing endoscopic procedures, reduces the length of stay in hospital for the patient, and reduces the cost of treatment by transferring therapy from the operating theatre to the endoscopy room.

Patients have now been successfully treated using the Speedboat device in the UK, South Africa, Mainland Europe and the US.